A further novel characteristic feature of the current WHO classification is that the diagnosis of “glioblastoma” will be reserved to IDH wildtype tumors, whereas IDH mutant WHO grade 4 lesions will be classified as “WHO grade 4 astrocytoma” (Louis et al., 2021). This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).